TY - JOUR T1 - Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy JF - medRxiv DO - 10.1101/2021.06.12.21258357 SP - 2021.06.12.21258357 AU - Juan F Vázquez-Costa AU - Mónica Povedano AU - Andrés E Nascimiento-Osorio AU - Antonio Moreno Escribano AU - Solange Kapetanovic Garcia AU - Raul Dominguez AU - Jessica M Exposito AU - Laura González AU - Carla Marco AU - Julita Medina Castillo AU - Nuria Muelas AU - Daniel Natera de Benito AU - Nancy Carolina Ñungo Garzón AU - Inmaculada Pitarch Castellano AU - Teresa Sevilla AU - David Hervás Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/15/2021.06.12.21258357.abstract N2 - Objective To assess in adult spinal muscular atrophy (SMA) patients the construct validity and responsiveness of several outcome measures.Methods Patients older than 15 years and followed-up at least for 6 months, between October 2015 and August 2020, with one motor function scale (Hammersmith Functional Motor Scale Expanded, HFMSE; Revised Upper Limb module, RULM) in five referral centers were included. Bedside functional scales (Egen Klassification, EK2; Revised Amyotrophic Lateral Sclerosis Functional Rating Scale, ALSFRS-R) were also collected when available. Correlations and regression models were performed to evaluate the construct validity. The monthly slopes of change were used to calculate their responsiveness.Results The study included 79 SMA patients, followed up for a mean of 16 months. All scales showed strong or very strong correlations with each other. A floor effect in motor function scales was found in weakest patients (HFMSE < 5 and RULM<10), and a ceiling effect in stronger patients (with HFMSE >55 and RULM > 35), when compared with other scales. ALSFRS-R (B=0.72) showed a strong discriminating ability between walkers, sitters, and non-sitters, and HFMSE (B=0.86) between walkers and sitters. The responsiveness was overall low, although in treated patients a moderate responsiveness was found for ALSFRS-R and HFMSE in walkers (0.69 and 0.61 respectively), and for EK2 in sitters (0.65) and non-sitters (0.60).Conclusions This study shows the validity in SMA adult patients of commonly used scales. Overall, bedside functional scales showed some advantages over motor function scales, although all scales showed low responsiveness in untreated patients.Competing Interest StatementThis study has received funding from FUNDAME (FUN-000-2017-01) and CUIDAME (PIC188-18). Dr. Vazquez-Costa is funded by grants of the Instituto de Salud Carlos III (JR19/00030, PI Vazquez), and received personal fees from Biogen and Roche outside the submitted work. Dr.Nascimento-Osorio received personal fees from Avexis, Biogen and Roche outside the submitted work; principal investigator for ongoing Biogen and Roche clinical trials. Dr. N. Muelas received personal fees from Biogen outside the submitted work. Dr. A. Moreno received personal fees from Biogen outside the submitted work. Dr. M Povedano received personal fees from Biogen and Roche outside the submitted work. Dr Solange Kapetanovic Garcia has nothing to disclose. Dr Raul Dominguez has nothing to disclose. Dr Jessica M Exposito has nothing to disclose. Dr Laura Gonzalez has nothing to disclose. Dr Carla Marco has nothing to disclose. Dr Julita Medina Castillo has nothing to disclose. Dr Daniel Natera de Benito has nothing to disclose. Dr Nancy Carolina Nungo Garzon has nothing to disclose. Dr. Pitarch-Castellano received personal fees from Avexis, Biogen and Roche outside the submitted work; principal investigator for ongoing Biogen clinical trial. Dr David Hervas has nothing to disclose.Funding StatementThis study has received funding from FUNDAME (FUN-000-2017-01), from CUIDAME (PIC188-18), from Instituto de Salud Carlos III (JR19/00030 PI JFVC, 19/01178 PI TS), and from Generalitat Valenciana (PROMETEO/ 2018/135, PI TS). The Centro de Investigacion Biomedica en Red de Enfermedades Raras (CIBERER) is initiative from the ISCIII. TS and JFVC are members of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD). Sponsors did not participate in the study design, data acquisition and analysis, data interpretation or in writing the article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee for Biomedical Research of Instituto de Investigacion Sanitaria la Fe and Fundacio Sant Joan de Deu. All the participants gave written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesJFVC and DH had full access to the database population used to create the study population. All data supporting our findings are available on reasonable request. ER -